Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3588MR)

This product GTTS-WQ3588MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3588MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6713MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ1980MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ488MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ9750MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ8582MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ5347MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ13426MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ8870MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW